Comparison of the Efficacy between Pemetrexed plus Platinum and Non-Pemetrexed plus Platinum as First-Line Treatment in Patients with Wild-Type Epidermal Growth Factor Receptor Nonsquamous Non-Small Cell Lung Cancer: A Retrospective Analysis | Citedby Results | Chemotherapy | Karger Publishers

Skip to Main Content

Skip Nav Destination

Comparison of the Efficacy between Pemetrexed plus Platinum and Non-Pemetrexed plus Platinum as First-Line Treatment in Patients with Wild-Type Epidermal Growth Factor Receptor Nonsquamous Non-Small Cell Lung Cancer: A Retrospective Analysis

Chemotherapy (2015) 61 (1): 41–50.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Comparison of Clinicopathogenomic Features and Treatment Outcomes of EGFR and HER2 Exon 20 Insertion Mutations in Non–Small Cell Lung Cancer: Single-Institution Experience

So Heun Lee
Hyehyun Jeong
Deok Hoon Kim
Se Jin Jang
Sang-We Kim
Shinkyo Yoon
Dae Ho Lee

Cancer Research and Treatment (2024) 56 (3): 774.

Effect of kangai injection combined with platinum-based chemotherapy on the immune function of patients with advanced non-small-cell lung cancer: A meta-analysis

Dongwei Zhu
Yong Xu
Fanchao Feng
Zhichao Wang
Di Han
Xianmei Zhou

Phytomedicine (2022) 100: 154088.

Identifying the Antitumor Effects of Curcumin on Lung Adenocarcinoma Using Comprehensive Bioinformatics Analysis

Fei-Ran Yang
Si-Yi Li
Xi-Wen Hu
Xiu-Rong Li
Hui-Jie Li

Drug Design, Development and Therapy (2022) Volume 16: 2365.

Nitroglycerin-induced downregulation of AKT- and ERK1/2-mediated radiation-sensitive 52 expression to enhance pemetrexed-induced cytotoxicity in human lung cancer cells

Jen-Chung Ko
Jyh-Cheng Chen
Pei-Yu Tseng
Jou-Min Hsieh
Chen-Shan Chiang
Li-Ling Liu
Chin-Cheng Chien
I-Hsiang Huang
Yun-Wei Lin

Toxicology Research (2022) 11 (2): 299.

Oral nutritional supplement prevents weight loss and reduces side effects in patients in advanced lung cancer chemotherapy

Piera Torricelli
Francesco Antonelli
Pasquale Ferorelli
Ilaria Borromeo
Anna Shevchenko
Stefano Lenzi
Angelo De Martino

Amino Acids (2020) 52 (3): 445.

Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer

Toshihiko Kaneda
Hiroshige Yoshioka
Motohiro Tamiya
Akihiro Tamiya
Akito Hata
Asukaka Okada
Takashi Niwa
Takayuki Shiroyama
Masaki Kanazu
Tadashi Ishida
Nobuyuki Katakami

BMC Cancer (2018) 18 (1)

Post-Progression Survival Associated with Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Docetaxel Monotherapy as Second-Line Chemotherapy

Mie Kotake
Yosuke Miura
Hisao Imai
Keita Mori
Reiko Sakurai
Kyoichi Kaira
Yoshio Tomizawa
Koichi Minato
Ryusei Saito
Takeshi Hisada

Chemotherapy (2017) 62 (4): 205.

Comparing approaches to the management of malignant pleural effusions

José M. Porcel
Macy Mei-Sze Lui
Andrew D. Lerner
Helen E Davies
David Feller-Kopman
Y.C. Gary Lee

Expert Review of Respiratory Medicine (2017) 11 (4): 273.

Effectiveness of Nivolumab versus Docetaxel as Second-Line Treatment in Non-Small Cell Lung Cancer Patients in Clinical Practice

Pablo Calpe-Armero
Rafael Ferriols-Lisart
Francisco Ferriols-Lisart
Alejandro Pérez-Pitarch

Chemotherapy (2017) 62 (6): 374.

Drug Resistance to EGFR Inhibitors in Lung Cancer

Osamu Tetsu
Matthew J. Hangauer
Janyaporn Phuchareon
David W. Eisele
Frank McCormick

Chemotherapy (2016) 61 (5): 223.